Trial reportFrontiers in medicine2025
Effects of hydromorphone-based patient-controlled intravenous analgesia on postpartum depression after cesarean section: a prospective randomized controlled trial.
Trial report in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postpartum depression (PPD) is a common mental health condition affecting 10-20% of women, particularly after cesarean delivery, which may hinder maternal recovery and breastfeeding. Hydromorphone, a semi-synthetic opioid with unique pharmacologic properties, has recently been applied in postoperative analgesia. This study aimed to evaluate the effects of hydromorphone-based patient-controlled intravenous analgesia (PCIA) on PPD and related maternal-infant outcomes after cesarean section. Methods: In this prospective, randomized, double-blind controlled trial, 120 parturients aged 20-40 years scheduled for elective cesarean section were randomly assigned to receive either sufentanil (Group S, Results: Compared with Group S, Group H had significantly lower EPDS scores on postoperative days 3 and 42, higher breastfeeding satisfaction at 72 h, and lower Ramsay sedation scores at 24 and 48 h (all Conclusion: Hydromorphone-based PCIA after cesarean section was associated with lower EPDS scores on postoperative days 3 and 42, improved breastfeeding satisfaction at 72 h, and a lower incidence of dizziness and drowsiness. Clinical trial registration: www.chictr.org.cn, identifier ChiCTR2500105264.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.